|04/23/14||The Medicines Company Reports First Quarter 2014 Financial Results|
|First Quarter Net Revenues Rise 14%, Adjusted Net Income(1) Rises 25%; Company Continues Year-Over-Year Growth in Revenue
PARSIPPANY, NJ -- (Marketwired) -- 04/23/14 --
The Medicines Company (NASDAQ: MDCO), a global company focused on saving lives, alleviating suffering, and improving the economic efficiency of the world's leading hospitals, today announced first quarter financial results for 2014.
Highlights for the first quarter of 2014:
Worldwide net revenue increased by 14% to $177.2 m... |
|04/23/14||The Medicines Company Adds Novel, Approved, Surgical Sealant to Its Surgical Hemostasis Portfolio|
|Acquires Tenaxis Medical, Inc.
PARSIPPANY, NJ and MOUNTAIN VIEW, CA -- (Marketwired) -- 04/23/14 --
The Medicines Company (NASDAQ: MDCO) and Tenaxis Medical, Inc. (Tenaxis) today announced an agreement for The Medicines Company to acquire Tenaxis. Tenaxis's sole product, which mechanically seals both human tissue and artificial grafts is approved, but not launched in the US -- having received US PMA approval from the FDA in March 2013 as a vascular sealant. The product is also approved with a ... |
|04/09/14||The Medicines Company to Announce First Quarter 2014 Financial Results on Wednesday, April 23, 2014|
|Conference Call to Be Held at 8:30 a.m. Eastern Time
PARSIPPANY, NJ -- (Marketwired) -- 04/09/14 --
The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, April 23 at 8:30 a.m. Eastern Time to discuss first quarter 2014 financial results, operational developments, and outlook for 2014.
The conference call will be available via phone and webcast. The dial-in information is listed below:
Domestic Dial In: + 1 877-359-9508
International Dial ... |
|04/03/14||FDA Accepts the Filing of The Medicines Company's US Biologic License Application for Fibrocaps Hemostatic Agent|
|PARSIPPANY, NJ -- (Marketwired) -- 04/03/14 --
The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a biologic license application (BLA) for the investigational hemostatic agent Fibrocaps, a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery, where control of mild or moderate bleeding by conventional means is ineffective or impractical. The FDA action date (PDUFA date)... |